DEEP RESEARCH · PHAROS IBIO

Pharos iBio (388870) — The First Korean AI Drug Discoverer to Cross the 'River of Validation'

PHI-101 Global Phase 1 CRc 50% / ORR 67% — the sector has shifted from 'platform hype' to 'clinical validation'.

Date: 2025-11-08 · Personal research notes (analyst tone) · Sources: DART/KRX filings, Pharos iBio IR, Edaily/Daily Pharm/Korea Biomed and others

I. Bottom line first — from 'platform hype' to 'clinical validation'

Official fact: On 1 July 2025, Pharos received the Clinical Study Report (CSR) for the global Phase 1 of PHI-101 in relapsed/refractory acute myeloid leukemia (r/r AML), confirming a composite complete remission (CRc) of 50% and overall response rate (ORR) of 67%. PHI-101 has Orphan Drug Designation (ODD) from the US FDA, EU EMA and Korea MFDS.

Interpretation: While competitors keep highlighting 'automation, speed, SaaS/FFS' platform attributes, Pharos has moved up to the next valuation tier — a company holding a clinically validated drug discovered by its platform. The data is at a level that supports immediate licensing talks.

Key Opportunities

• Data-backed L/O leverage: With the PHI-101 CSR in hand, Pharos enters Big Pharma licensing negotiations with real bargaining power.
• Maximum beneficiary of the 'K-AI drug discovery' policy: As the 'first Korean AI-discovered drug to succeed in the clinic', Pharos is the most credible policy poster child.

Key Risks

• Near-term overhang: One month after IPO, VC lock-up expired on 33.2% of total shares (4,289,340 shares held by 19 investors).
• Cash burn: As PHI-101 Phase 2 and PHI-501 Phase 1 accelerate, additional financing will likely be needed from H2 2025 onward.

II. Company overview — the 'Chemiverse' AI platform and the business model

Pharos iBio is an R&D-focused biotech that discovers drug candidates in-house using its proprietary AI drug discovery platform, Chemiverse®. Its revenue strategy runs on two parallel tracks.

The Chemiverse® platform — 9 modules

Chemiverse covers the early stages of drug discovery (target identification through candidate derivation). It is built on a big-data foundation of approximately 6.2 billion 3D protein structures and chemical compounds, combined with state-of-the-art deep learning (transformer-based generative models). Core modules include:

The real moat — 'predictions validated as clinical fact'

Interpretation: The Chemiverse moat is not the module count — it is the fact that the predictions were proven in the clinic. PHI-101-AML was deliberately designed using Chemiverse's cardiotoxicity prediction module to avoid the chronic cardiotoxicity issues of legacy FLT3 inhibitors. The 2025 July global Phase 1 CSR formally confirmed that no serious cardiotoxicity was observed even at the highest dose — a complete loop of 'design → predict → prove'.

Chemiverse drug discovery flow

Customers and partners

• Potential L/O customers: Global Big Pharma. Currently engaged at BIO-USA, BIO-Europe 2025 and other major partnering events.
• Johns Hopkins University: Translational research on PHI-101 combination therapy (with azacitidine or venetoclax) with the lab of Prof. Donald Small, a global AML authority. Prof. Small also advises on PHI-101 global Phase 2 design and the US clinical site network (KBR).
• The University of Sydney: In May 2023, through its Australian subsidiary (Pharos Therapeutics), Pharos signed an MOU with the Sydney Drug Discovery Initiative. Pharos provides Chemiverse; Sydney provides research infrastructure for joint oncology and rare disease discovery.
• Major hospitals: PHI-101 multinational Phase 1 ran with Seoul National Univ. Hospital, Seoul St. Mary's, Asan Medical Center, Samsung Medical Center, Pusan National Univ. Hospital and Australia's ICON Cancer Centre.

III. Financial health — a textbook 'invest and develop' biotech cash flow

As a pre-L/O R&D biotech, Pharos's cash flow shows the classic 'investing and developing' profile. Specific 2021-2023 cash flow figures are not directly available in the public summary, but qualitatively the picture is clear.

Interpretation: 'Pre-IPO funding (2021) → IPO (2023)' is the textbook Korean biotech funding path. As of 2025, the IPO proceeds are being drawn down — the next financing event (an L/O upfront or another raise) is approaching.

Multi-layered moat

• Clinical data validation — objective proof of platform credibility.
• Johns Hopkins collaboration — intangible asset that gives potential L/O partners technical trust via a world-class AML KOL.
• Government 'K-AI drug discovery' policy ramping up — 'first-in-Korea' symbolism opens the door to R&D grants, tax incentives and lighter-touch regulation.

IV. Corporate history and key management

Milestones

• Apr 2016: Pharos iBT Inc. founded (later renamed Pharos iBio Inc.).
• 2019: PHI-101 receives US FDA Orphan Drug Designation (ODD) for AML.
• Mar 2021: PHI-101 IND additionally approved by Korea MFDS for ovarian cancer.
• Jun 2021: Series C of USD 15.9M (~KRW 18B) closed.
• Nov 2021: PHI-501 receives US FDA ODD for malignant melanoma.
• May 2023: MOU on AI-based drug discovery joint research with the University of Sydney.
• 27 Jul 2023: KOSDAQ technology-special listing.
• Mar 2025: PHI-501 Phase 1 IND filed with MFDS.
• Jun 2025: PHI-501 Phase 1 IND approved by MFDS.
• 1 Jul 2025: PHI-101 (AML) global Phase 1 CSR received — CRc 50%, ORR 67%, with strong safety.

Key people

V. Capital raises and shareholder structure

Last 5 years of major funding

• Series C (Jun 2021): USD 15.9M (~KRW 18B). Lead investors include Company K Partners, UTC Investment, Korea Investment Holdings, Mirae Asset Venture Investment and other institutions.
• IPO (Jul 2023): KOSDAQ technology-special listing. At the offering range of KRW 14,000-18,000, total proceeds were ~KRW 19.6B to 25.2B.

Shareholders at listing

• CEO Jeonghyeok Yoon: 21.21%.
• Related parties (Nam Ki-yeop and 11 others): 11.57%.
• Management voluntarily extended their mandatory holding period by 2 years on top of the original 1 year — for a total 3-year lock-up.
• Total VC stake: approximately 12.5% pre-IPO. Includes Company K Partners (deep-tech focus) and UTC Investment (active in innovative biotechs such as Cureverse, RZNomics and Inserve-Bio).

Interpretation: The contrast between the 3-year management lock-up and the VC tranche unlocking just one month after IPO is stark — a strong management-confidence signal coexisting with a real near-term supply overhang.

VI. Competitive landscape (Korean AI drug discovery)

Pharos iBio is part of the first-generation Korean AI drug discovery cohort alongside Standigm (private) and Syntekabio (226330.KQ). All use AI, but the platforms and business models differ sharply.

Interpretation: Standigm emphasizes 'speed and automation' end-to-end but lacks a late-clinical asset. Syntekabio differentiates with its proprietary ABSC supercomputing 'AI-DC Full-Stack' infrastructure — but Pharos leads on the objective metric of 'AI-discovered drug passes Phase 1'. The global benchmark is Recursion Pharmaceuticals. As the sector enters its 'winners and losers' phase, the market will reward 'companies with clinically validated AI-discovered drugs' overwhelmingly more than 'companies with platforms'.

VII. Core pipeline overview

Pipeline cards

VIII. Growth strategy and the last 8 quarters of investment

Mid-2023 to mid-2025 strategy was clear: use IPO proceeds to accelerate the core clinical pipeline.

• R&D-focused investment: Of the ~KRW 19.6B in IPO proceeds (Jul 2023), approximately KRW 15.5B earmarked for PHI-101 global Phase 2 prep and PHI-501 Phase 1 entry (Daily Pharm).
• Global footprint: Australian (Pharos Therapeutics) and US subsidiaries serve as R&D and BD outposts — enabling efficient multinational trials plus direct IR at BIO-USA and BIO-Europe.
• Management confidence signal: Immediately after receiving the positive PHI-101 CSR in July 2025, CEO Yoon expressed 'L/O confidence' and personally purchased company shares — a simultaneous signal of clinical conviction and shareholder alignment.

IX. Potential risks

1. Overhang risk — near-term, very high impactOfficial fact: One month after the 27 July 2023 listing, lock-up expired on 4,289,340 shares held by 19 investors including Company K High-Growth Fund — equal to 33.2% of total outstanding shares.

Interpretation: These VCs are financial investors from Series C and earlier — their primary aim is exit. Their supply pressure operates independently of fundamentals. Near-term price action and fundamentals will decouple in this window.

2. Management's risk response — positive

• Management lock-up: CEO Yoon and key managers voluntarily extended lock-up by 2 years for a total 3-year period.
• Put-back option: Lead underwriter Korea Investment & Securities granted a put-back option at 90% of the offering price for six months after listing.
• Share buyback: On 1 July 2025, immediately after the positive PHI-101 CSR announcement, CEO Yoon personally bought back shares — simultaneously a clinical-confidence and price-defense signal.

3. Capital risk — medium-term, moderate impact

Official fact: As of early 2024, the company held approximately 1.5 years of R&D cash. PHI-101 global Phase 2 and PHI-501 Phase 1 acceleration will inevitably speed up burn.

Official fact: Per the corporate charter, the combined ceiling for BW and CB issuance is set at KRW 50B.

Interpretation: An additional raise is likely needed in H2 2025 or early 2026. However, the strong Phase 1 data acts as a 'negotiation card' — if a rights offering or CB/BW becomes necessary, Pharos can secure favorable terms (higher share price, lower coupon). The R&D financing risk has been materially mitigated by the PHI-101 data.

X. Top Pick analysis — 3-year outlook and policy tailwinds

Macro tailwind 1 — Government policy

National strategic agenda: 'Becoming a global hub in bio and digital health' is selected as one of the current government's top-120 national agenda items.

Focus on AI drug discovery: Strategic investment in AI-based digital healthcare, pharma, and medical devices.

Budget expansion: The 2026 budget allocates KRW 10.1T to AI in aggregate, and R&D itself is set at an all-time high of KRW 35.3T, up 19.3%.

Interpretation: The next three years are when the government desperately needs 'AI drug discovery success stories'. Pharos — which delivered the policy's KPI as 'CRc 50% in a global Phase 1' — has the strongest claim to be the policy 'poster child'.

Macro tailwind 2 — Sector paradigm shift to validation

The AI drug discovery sector has moved past 'platform 1.0' (selling possibilities) into 'platform 2.0' (proving real value in the clinic). Globally, there are very few examples of AI-discovered molecules successfully completing Phase 1.

Why Pharos is Top Pick

Key 3-year price catalysts

• PHI-101 global Phase 2 entry and data readout (2026-2027).
• PHI-101 L/O contract with global Big Pharma (2026-2027).
• PHI-501 Phase 1 efficacy readout and combo-trial expansion (2027).